Abigail Brooks, MA

In addition to being less likely to become pregnant, women with alcohol-associated hepatitis faced a greater risk of adverse pregnancy outcomes.

Kidney transplant recipients who received a GLP-1 RA had a 49% lower incidence of death-censored graft loss and 31% lower mortality.

The FDA approved the sNDA for furosemide (Furoscix) to expand the indication to include treatment of edema in patients with CKD.

In part 2 of this episode of Crisis Point, 3 nephrology experts and a patient advocate discuss strategies to address the CKD crisis.

Maternal vaccination during pregnancy with the Tdap or seasonal influenza vaccine was associated with greater odds of newborn receipt of the HepB vaccine.

In part 1 of this episode of Crisis Point, 3 nephrology experts and a patient advocate discuss CKD’s emergence as a public health crisis.

The gastroenterology month in review spotlights GI FDA news, research about colorectal cancer and alcohol complications, and new data for mirikizumab.

Anouti discusses the new AAP biliary atresia guidance and what it means to him as a patient-advocate who had biliary atresia as an infant.

The nephrology month in review spotlights HCPLive’s coverage of renal trial developments, xenotransplant, new AKI guidance, and research about dialysis.

ChatGPT offered valuable individualized nutritional recommendations for MASLD management, but they did not fully align with established guidelines.

The hepatology month in review spotlights HCPLive’s coverage of hepatic drug development and research about GLP-1 RAs, viral hepatitis, and MASH.

The guidance is intended to inform the transition to outpatient care for patients with AKI-D and help care teams identify early signs of recovery.

Stine explains key components of a new multidisciplinary MASLD care model and how it improves upon preexisting models.

In adolescents and young adults, gastrointestinal complications from alcohol are increasing at greater rates than other organ systems.

Stine explains the continued need for diet and exercise in MASH and the importance of a multidisciplinary approach to treating these patients.

Positive 2-year results from the open-label compensated MASH cirrhosis arm of the MAESTRO-NAFLD-1 trial highlight resmetirom’s impact on liver stiffness.

Survey findings highlight pediatric nephrologists’ reluctance to list patients with kidney failure due to C3G or IC-MPGN for kidney transplantation.

A novel fast-track protocol was linked to a lower incidence of delirium and reduced LOS after transplant without increasing rejection and readmission risk.

Despite decreasing death rates, an analysis of GBD 2021 data highlights the increasing incidence of cirrhosis and other chronic liver diseases.

HCV screening in pregnant women increased following universal screening guidelines, but the proportion of women who were ever tested remained low.

From 1990-2021, the ASIR, ASMR, and age-standardized DALY rate of chronic kidney disease increased.

The analysis of US healthcare claims data suggests noninvasive methods are being used more often than liver biopsies for the diagnosis of MASH.

Patients with PBC and severe pruritus had worse HRQoL, greater rates of depression, and more sleep interference than those with mild/moderate pruritus.

The strategy detailed in the guidance aids the early identification of infants with biliary atresia and is intended for use between 2 and 4 weeks of life.

Low and high second-trimester eGFR values were linked to adverse pregnancy outcomes, including preeclampsia, preterm birth, low birth weight, and fetal loss.

The multidisciplinary care model included 7 co-located specialists who aided patient education, lifestyle intervention, and drug therapy strategies for MASH.

Amneal Pharmaceuticals launched mesalamine 800 mg delayed-release tablets for UC and received FDA approval for various lenalidomide doses for blood cancers.

Chemomab completed an end-of-phase 2 meeting with the FDA and has aligned on the design of a phase 3 registration study for nebokitug (CM-101) in PSC.

HDV RNA-positive patients were more often diagnosed with advanced liver fibrosis and had a 4.7-fold greater risk of severe liver-related outcomes.

A patient with decompensated liver cirrhosis treated with Namodenoson under a compassionate use program experienced improvements in disease at 20 months.